Payment overview · 2025
General Payments
$383.05
13 reported records · 9 companies
Healthcare provider profile · identity verified
Robert Slade Thacker, APRN CFNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CALDWELL, ID · NPI 1124309224
Verified facts
What the public records show
CMS Open Payments records show Robert Slade Thacker, APRN CFNP received $383.05 in general payments during 2025 across 13 reported records.
JAZZ PHARMACEUTICALS INC. accounted for 39.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt, Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XELJANZ as an associated drug or biological on 32588 records involving 8614 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xeljanz by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $150.00 | 39.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $91.03 | 23.8% | 5 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $25.51 | 6.7% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.34 | 6.1% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $20.87 | 5.5% | 1 | 2025 |
| Exeltis, USA Inc. | Unresolved — no canonical attribution shown | $20.73 | 5.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.89 | 4.9% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.43 | 4.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.25 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $233.05 | 12 |
| Consulting Fee | $150.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XYREM Normalized: xyrem |
Drug | JAZZ PHARMACEUTICALS INC. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $67.08 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $67.08 | 4 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $25.51 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $23.34 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA INITIO Normalized: aristada initio |
Drug | Alkermes, Inc. | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| SLYND Normalized: slynd |
Drug | Exeltis, USA Inc. | $20.73 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 99 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
99 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
115 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XELJANZ open payments reported associated product |
CMS Open Payments — General Payments 32588 supporting records · 8614 recipient NPIs · example record 1228794176 |
Xeljanz · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 549 | 157 |
| Levothyroxine Sodium | Levothyroxine Sodium | 525 | 148 |
| Lisinopril | Lisinopril | 384 | 107 |
| Gabapentin | Gabapentin | 333 | 74 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 325 | 53 |
| Omeprazole | Omeprazole | 302 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 298 | 82 |
| Metformin Hcl | Metformin Hcl | 274 | 73 |
| Losartan Potassium | Losartan Potassium | 235 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 170 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 161 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 144 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 42 |
| Furosemide | Furosemide | 136 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 131 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 124 | 45 |
| Trazodone Hcl | Trazodone Hcl | 120 | 39 |
| Eliquis | Apixaban | 115 | 30 |
| Potassium Chloride | Potassium Chloride | 115 | 37 |
| Tramadol Hcl | Tramadol Hcl | 115 | 29 |
| Meloxicam | Meloxicam | 114 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 105 | 35 |
| Pregabalin | Pregabalin | 102 | 18 |
| Alprazolam | Alprazolam | 100 | 17 |
| Ozempic | Semaglutide | 99 | 22 |
| Bupropion Xl | Bupropion Hcl | 98 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 98 | 29 |
| Prednisone | Prednisone | 98 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 92 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 24 |
| Mounjaro | Tirzepatide | 88 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 26 |
| Metformin Hcl Er | Metformin Hcl | 82 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 24 |
| Trulicity | Dulaglutide | 81 | 23 |
| Montelukast Sodium | Montelukast Sodium | 79 | 26 |
| Sertraline Hcl | Sertraline Hcl | 77 | 17 |
| Allopurinol | Allopurinol | 74 | 17 |
| Buspirone Hcl | Buspirone Hcl | 72 | 20 |
| Famotidine | Famotidine | 71 | 21 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 68 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 68 | 12 |
| Ezetimibe | Ezetimibe | 67 | 19 |
| Simvastatin | Simvastatin | 67 | 21 |
| Alendronate Sodium | Alendronate Sodium | 66 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 63 | 11 |
| Propranolol Hcl | Propranolol Hcl | 62 | 14 |
| Estradiol | Estradiol | 61 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 16 |
| Fenofibrate | Fenofibrate | 58 | 17 |
| Mirtazapine | Mirtazapine | 56 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 15 |
| Diazepam | Diazepam | 52 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 12 |
| Xarelto | Rivaroxaban | 47 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 12 |
| Spironolactone | Spironolactone | 45 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 41 | 13 |
| Clonazepam | Clonazepam | 40 | suppressed |
| Finasteride | Finasteride | 40 | 12 |
| Invega Sustenna | Paliperidone Palmitate | 40 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | 11 |
| Carvedilol | Carvedilol | 39 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 22 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | 11 |
| Atenolol | Atenolol | 38 | suppressed |
| Aripiprazole | Aripiprazole | 36 | suppressed |
| Glipizide | Glipizide | 36 | suppressed |
| Glimepiride | Glimepiride | 35 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Bumetanide | Bumetanide | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Olanzapine | Olanzapine | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 30 |
| Lorazepam | Lorazepam | 30 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | 16 |
| Baclofen | Baclofen | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 23 | suppressed |
| Nystatin | Nystatin | 23 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 16 |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Rybelsus | Semaglutide | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Xeljanz | Tofacitinib Citrate | 14 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tri-Lo-Marzia | Norgestimate-Ethinyl Estradiol | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $383.05 · 13 records | JAZZ PHARMACEUTICALS INC. | ARISTADA, ARISTADA INITIO, EVENITY, FANAPT, NURTEC ODT, Ozempic, PROLIA, Rybelsus, SLYND, Wegovy, XYREM, XYWAV, YUPELRI, ZAVZPRET, ZURZUVAE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error